Postinjury Hyperfibrinogenemia Compromises Efficacy of Heparin-Based Venous Thromboembolism Prophylaxis

Background Venous thromboembolism (VTE) prophylaxis remains debated following trauma, and recommendations have not been established. Although hyperfibrinogenemia is a marker of proinflammatory states, it also contributes to thrombus formation. Postinjury hyperfibrinogenemia is common, but the effect of hyperfibrinogenemia on VTE prophylaxis has not been fully elucidated. Therefore, we hypothesized that heparin is less effective for VTE prophylaxis following severe injury due to hyperfibrinogenemia. Methods In vitro studies evaluated thromboelastography (TEG) parameters in 10 healthy volunteers after the addition of fibrinogen concentrate and heparin. Data from a recent randomized controlled trial, conducted at an academic level I trauma center surgical intensive care unit, were reviewed. Critically injured patients were randomized to standard VTE prophylaxis (5,000 U low-molecular-weight heparin daily) or TEG-guided prophylaxis (up to 10,000 U low-molecular-weight heparin daily) and were followed up for 5 days. Analysis was performed to evaluate the relationship between fibrinogen levels, measures of anticoagulation, and TEG parameters. Results In vitro studies revealed increased fibrinogen reversed the effects of heparin as measured by TEG. Fifty patients were enrolled in the clinical study with 25 in each arm. Thromboelastography parameters, fibrinogen, platelet count, and anti-Xa levels did not differ between groups despite treatment provided. Fibrinogen levels increased over the 5-day study period (597 ± 24.0 to 689.3 ± 25.0), as well as clot strength (9.8 ± 0.4 to 14.5 ± 0.6), which had a significant correlation coefficient (P < 0.01). Moreover, there was a moderate inverse correlation between fibrinogen level and the effect of heparin (RF), which was significant on study days 1 and 3, implicating hyperfibrinogenemia in heparin resistance. Conclusions Hypercoagulability and heparin resistance are common following trauma. The preclinical and clinical relationships between fibrinogen levels and hypercoagulability implicate hyperfibrinogenemia as a potential factor in heparin resistance.

[1]  A. Sauaia,et al.  Platelets are dominant contributors to hypercoagulability after injury , 2013, The journal of trauma and acute care surgery.

[2]  A. Sauaia,et al.  FUNCTIONAL FIBRINOGEN ASSAY INDICATES THAT FIBRINOGEN IS CRITICAL IN CORRECTING ABNORMAL CLOT STRENGTH FOLLOWING TRAUMA , 2013, Shock.

[3]  J. Gallacher,et al.  C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[4]  M. Cohen,et al.  Characterization of platelet dysfunction after trauma , 2012, The journal of trauma and acute care surgery.

[5]  A. Sauaia,et al.  Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. , 2012, Journal of the American College of Surgeons.

[6]  W. Voelckel,et al.  Early and individualized goal-directed therapy for trauma-induced coagulopathy , 2012, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

[7]  D. Hak,et al.  Deep Vein Thrombosis Prophylaxis in Trauma Patients , 2011, Thrombosis.

[8]  A. Wolberg,et al.  Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. , 2011, Blood.

[9]  D. Hoyt,et al.  Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. , 2010, The Journal of trauma.

[10]  K. Mann,et al.  Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. , 2009, The Journal of trauma.

[11]  M. Schreiber,et al.  Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. , 2009, The Journal of trauma.

[12]  K. Raghavendran,et al.  Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. , 2005, The Journal of trauma.

[13]  P. Rhee,et al.  Thromboprophylaxis Does Not Protect Severely Injured Patients against Pulmonary Embolism , 2004, The American surgeon.

[14]  L. Washington,et al.  Incidence of asymptomatic pulmonary embolism in moderately to severely injured trauma patients. , 2004, The Journal of trauma.

[15]  Sergiy Yakovlev,et al.  Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site. , 2003, Biochemistry.

[16]  C. Mannhalter,et al.  Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[17]  W. Koenig.  Fibrin(ogen) in cardiovascular disease: an update , 2003, Thrombosis and Haemostasis.

[18]  D. Farrell,et al.  Fibrinogen γ′ chain binds thrombin exosite II , 2003 .

[19]  B. Furie,et al.  Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse , 2002, Nature Medicine.

[20]  D. Monroe,et al.  A Cell-based Model of Hemostasis , 2001, Thrombosis and Haemostasis.

[21]  J. Johannigman,et al.  The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis. , 2000, Surgery.

[22]  G. Di Minno,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[23]  W. T. Morgan,et al.  Histidine-Proline-rich Glycoprotein as a Plasma pH Sensor , 1998, The Journal of Biological Chemistry.

[24]  T. Odrljin,et al.  Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. , 1996, Blood.

[25]  P. Hogg,et al.  Inhibition of heparin activity in plasma by soluble fibrin: evidence for ternary thrombin-fibrin-heparin complex formation. , 1994, Blood.

[26]  P. Reitsma,et al.  Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis , 1994, Thrombosis and Haemostasis.

[27]  J. Hirsh,et al.  Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins , 1993, Thrombosis and Haemostasis.

[28]  P C Elwood,et al.  Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.

[29]  S. Shackford,et al.  Venous thromboembolism in patients with major trauma. , 1990, American journal of surgery.

[30]  T. Fabian,et al.  Silent deep vein thrombosis in immobilized multiple trauma patients. , 1989, American journal of surgery.

[31]  S. Olson,et al.  Binding of heparin to human high molecular weight kininogen. , 1989, Biochemistry.

[32]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[33]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[34]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[35]  Oxon Dm.  Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[36]  D. Farrell,et al.  Fibrinogen gamma' chain binds thrombin exosite II. , 2003, Journal of thrombosis and haemostasis : JTH.

[37]  M. Mancini,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction. , 1990, Arteriosclerosis.